A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)
Yinghui Jin(Wuhan University), Xinghuan Wang(Wuhan University), Jian‐Chuan Xia(Sun Yat-sen University), Yingwen Zhang(Shanghai Jiao Tong University), Yong Han(Wuhan University), Xuequn Ren(Henan University Huaihe Hospital and Huaihe Clinical Institute), Chaojie Wei(Zhongnan Hospital of Wuhan University), Zhiyong Peng(Wuhan University), Yunbao Pan(The University of Texas MD Anderson Cancer Center), Xiaomei Yao(Impact), Dong-Fang Wu(Wuhan University), Yin-Gao Zhang(Wuhan University), Ming-Juan Zhao(Wuhan University), Taisheng Ye(Wuhan University), Xian‐Tao Zeng(Wuhan University), Ying Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Likai Lin(Wuhan University), Lin Cai(Wuhan University), Huimin Sun(Wuhan University), Cheng Fang(Wuhan University), Yong Xiong(Wuhan University), Hong Cheng(Capital Medical University), Yipin Fan(Chinese Academy of Medical Sciences & Peking Union Medical College), Hao Zi(Qilu University of Technology), Yufeng Yuan(Wuhan University), Xiaochun Zhang(Wuhan University), Bo Hu(Wuhan University), Luqi Huang(Shenyang Pharmaceutical University), Yirong Li(Wuhan University), Tong Deng(Henan University), Jing Ma(Uppsala University), Binghui Li(Tianjin Medical University Cancer Institute and Hospital), Huamin Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongyan Wang(Beijing Normal University), Yan Zhao(Wuhan University), Zhenshun Cheng(Wuhan University), Ke Liang(Wuhan University), Di Huang(Wuhan University), Haibo Xu(Wuhan University), Qiao Huang(Wuhan University), Linlu Ma(Wuhan University), Fen Hu(Wuhan University), Hong Weng(Wuhan University), Zhenyu Pan(Wuhan University)
Cited by 2,363
Related Papers
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
|The Lancet|2020|51.8k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?
|Military Medical Research|2020|1.6k
Novel mutations target distinct subgroups of medulloblastoma
|Nature|2012|853